Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

Shanghai Zhimeng Biopharma Inc. ( 'Zhimeng') announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially ...

First orphan designation ever granted to a condensate-modulating therapeuticBuilds on recent IND opening for DPTX3186, a ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Aldeyra Therapeutics reports positive results from phase 2 clinical trial in alcohol-connected hepatitis: Lexington, Massachusetts Thursday, October 30, 2025, 17:30 Hrs [IST] Alde ...

In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%. ・Ardelyx’s net ...

IMM-529 IND: currently under review, FDA request for Information - minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data ...

Purple said that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future ...

Over the past generation, advances in treating common cancers—breast, lung, melanoma, and gastrointestinal (GI)—have improved ...

IMM-529 IND: currently under review, FDA request for Information - minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data de ...